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DImproved survival after coronary artery bypass grafting has not
influenced the mortality disadvantage in patients with diabetes
mellitus
Thomas Alserius, MD, PhD,a,c Niklas Hammar, PhD,d Tobias Nordqvist, MSc,b and
Torbjo¨rn Ivert, MD, PhDa,c
Objectives: We sought to compare mortality after coronary artery bypass grafting in patients with and without
diabetes mellitus undergoing operations during different time periods.
Methods: We performed analyses of 12,415 primary isolated coronary artery bypass grafting operations
performed during 1970–2003, with follow-up of 5-year mortality up to December 2006.
Results: The prevalence of diabetes mellitus continuously increased up to 25% among patients undergoing cor-
onary artery bypass grafting in 2003. The 1892 patients with type 2 diabetes mellitus were older, more often
female, and more frequently had cardiovascular risk factors, acute coronary syndrome, 3-vessel disease, and
severely reduced left ventricular function than patients without diabetes mellitus. Early mortality was 3.4% in
patients with diabetes mellitus versus 1.8% in patients without diabetes mellitus. The multivariable adjusted
odds ratio was 2.0, and the 95% confidence interval was 1.4 to 2.7. Early adjusted mortality was significantly
lower in patients operated on during 2000–2003 than those operated on during 1970–1989 in patients with dia-
betes mellitus (odds ratio, 0.3; 95% confidence interval, 0.1–0.9) and without diabetes mellitus (odds ratio, 0.4;
95% confidence interval, 0.2–0.7). Mortality until 5 years was 14.6% in patients with diabetes mellitus versus
8.3% in patients without diabetes mellitus (hazard ratio, 1.8; 95% confidence interval, 1.5–2.0). Five-year mor-
tality was reduced by 40% in patients operated on during 2000–2003 compared with that seen in those operated
on during 1970–1989 in patients with and without diabetes mellitus.
Conclusions: Diabetes mellitus was associated with an almost 2-fold increased risk of early and 5-year mortality.
Early and late mortality were substantially reduced in patients with and without diabetes mellitus operated on
more recently, but the mortality disadvantage associated with diabetes mellitus was not eliminated.
Alserius et al Acquired Cardiovascular DiseasePatients with diabetes mellitus (DM) have a generalized vas-
cular disease and often extensive coronary artery disease
with diffuse peripheral obstructive lesions.1-4 Many studies
have documented higher early mortality after coronary artery
bypass grafting (CABG) in patients with DM than in those
without DM.1,5-9 In other reports early mortality did not dif-
fer.10-14 DM is in most reports recognized as an independent
predictor of 5-year mortality after CABG.8,10,11,15-18
Conversely, Calafiore and colleagues,6 who used multiple
arterial grafts, did not find that DM, exclusive of patients
with diet treatment, was associated with a worse 5-year mor-
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tients with insulin-treated DM than in those taking oral
hypoglycemic medication.1,8,13,14,16,17 During recent years,
there has been substantial attention to risk factor reduction
in patients with cardiovascular disease and improvements
in the management of patients with DM that might have re-
duced the mortality disadvantage associated with DM.
The purpose of our study was to analyze mortality up to 5
years after a first isolated CABG operation performed during
more than 3 decades in patients with and without type 2 DM
to examine whether mortality differed in the 2 groups and
whether any difference was influenced by changes in sur-
vival prognosis related to the time period of the operation.
MATERIALS AND METHODS
Patients
From June 1970, when the first CABG operation was performed in Swe-
den, through December 2003, a total of 12,557 patients had a first-time iso-
lated CABG operation at the Karolinska University Hospital in Stockholm.
Demographic variables and clinical characteristics that are continuously re-
corded in the department database were validated. This information, as well
as information extracted by means of review of medical records, was used
for the present study. In patients with DM, the year of diagnosis, as well
as the type and dose of medication, was recorded. In total, 2034 (16%) pa-
tients had DM, 142 of whom (7%) had type 1 DM. The latter patient grouprdiovascular Surgery c Volume 138, Number 5 1115
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ACE ¼ angiotensin-converting enzyme
BMI ¼ body mass index
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
DM ¼ diabetes mellitus
HR ¼ hazard ratio
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
was small, with an average age 11 years less than that of patients with type 2
DM. Our analyses were confined to the 1892 patients with type 2 DM and
the 10,523 patients without a diagnosis of DM. Throughout the long time
period, major improvements were introduced regarding operative tech-
nique, myocardial protection, perioperative management, and pharmaco-
logic treatment of diabetes and cardiovascular risk factors. From 1983, all
patients routinely received lifelong treatment with 160 mg of acetylsalicylic
acid daily from the first postoperative day after CABG. Use of angiotensin-
converting enzyme (ACE) inhibitors increased from 22% during 1996–
1999 to 35% during 2000–2003, and the corresponding use of statins
increased from 49% to 71%. The study was approved by the local ethics
committee in Stockholm.
Definitions
DM included patients admitted with a clinical diagnosis of DM who
were treated with insulin, oral medication, or both or had a diet regimen
only. In this report patients having a transient perioperative increase in
blood glucose levels were not classified as having DM. Type 2 DM was
usually initially not insulin dependent and frequently associated with insu-
lin resistance.
Body mass index (BMI) was calculated by dividing weight in kilograms
by the square of height in meters. Serum creatinine values were measured at
the time of hospital admission. Creatinine clearance was calculated by using
the equation of Cockroft and Gault.19 Normal renal function was defined as
a creatinine clearance of 80 mL/min or greater.
Acute coronary syndrome was defined as chest pain at rest on admittance
to the hospital or new onset or accelerated angina within 4 weeks of the op-
eration. Peripheral vascular disease was defined as a history of exertional
claudication, prior revascularization to the legs, or both. Normal left ventric-
ular function was defined as an ejection fraction of greater than 50%without
dilatation of the ventricle. Reduced left ventricular function was defined as
an ejection fraction of less than 50% but greater than 30%. Severely re-
duced left ventricular function was defined as a markedly dilated ventricle
with akinetic or hypokinetic segments and an estimated ejection fraction
of less than 30%.
Follow-up
Follow-up of mortality was performed by linking each subject’s Swedish
personal identification number to the National Cause of Death Register
1970–2002 and to the National Population Register for deaths occurring
between 2003 and December 2006. Early mortality was defined as death
occurring within 30 days of surgical intervention. All patients were followed
at least 3 years with regard to vital status.
Statistical Methods
Early mortality was compared in patients with and without DM and
multivariably adjusted by using odds ratios (ORs) from logistic regression
analyses. Crude and adjusted hazard ratios (HRs) of deaths within 5 years
after CABG were estimated by using Cox’s proportional hazard regres-1116 The Journal of Thoracic and Cardiovascular Susion. Mortality was analyzed separately for early deaths and for deaths oc-
curring from 30 days until 5 years after the operation among survivors at
30 days. All variables listed in Table 1 were considered for inclusion in the
multivariable models. In the final analyses adjustment was made for con-
founding factors by using a change-in-point estimate approach. Variables
that changed the OR or HR by at least 0.1 when adjusted for in the mul-
tivariable analyses were included in the final model. Estimates of ORs and
HRs were accompanied by asymptotic 95% confidence intervals (CIs). In
the multivariable analyses age, BMI, and creatinine clearance were in-
cluded in the models as continuous variables, and other variables were in-
cluded as dichotomous variables, representing the presence or absence of
the characteristic. Year of surgical intervention was divided into the 3 time
periods of 1970–1989, 1990–1999, and 2000–2003 because there were
few patents with DM during the initial 2 decades. Left ventricular function
was categorized as normal, reduced, or severely reduced. Continuous vari-
ables are presented as the mean with 1 standard deviation. The Student’s t
test was used to compare differences in means between patient groups. The
logarithm of values was used in case of skewed distributions. The c2 test
or the 2-tailed Fisher’s exact test was used to compare categorical data.
Kaplan–Meier estimates of survival up to 5 years after surgical interven-
tion were calculated.
RESULTS
During the 34 years from 1970 through 2003, patients
having type 2 DM undergoing CABG accounted for an in-
creasing proportion that was 25% in 2003 (Figure 1). The
initial 19 years up to 1989 included only 17% of the 1892
patients with type 2 DM. Throughout the 3 time periods of
1970–1989, 1990–1999, and 2000–2003, average age in-
creased, and cardiovascular risk factors, acute coronary
syndrome, 3-vessel disease, and left main stem stenosis be-
came increasingly more common in patients with and with-
out DM (Table 1). BMI, creatinine clearance, history of
previous myocardial infarction, and peripheral vascular dis-
ease remained essentially unchanged. An increasing pro-
portion of patients with DM had insulin treatment or oral
medication. Among 722 patients with insulin treatment,
202 (27%) also received oral hypoglycemic medication.
Year of diagnosis of DM until year of CABG was signifi-
cantly greater (P < .01) in patients operated on during
1990–1999 (15.6  16.0 years) than during 2000–2003
(9.5  8.9 years). Single-vessel disease became less com-
mon. During 2000–2003, almost 80% of the patients re-
ceived 3 to 4 or more distal coronary anastomoses. An
internal thoracic artery graft was inserted in 95% of pa-
tients from 1990, regardless of DM diagnosis.
Patients with DM were characterized by older age, higher
BMI and creatinine clearance values, higher preponderance
of female sex, hypertension, hyperlipidemia, acute coronary
syndrome, previous myocardial infarction and stroke,
peripheral vascular disease, 3-vessel disease, and severely
reduced left ventricular function than those without DM.
The number of coronary anastomoses did not differ in pa-
tients with and without DM.
Overall survival until 5 years was less in patients with DM
than in those without DM (Figure 2). Survival was lowest in
patients with DM undergoing CABG during 1970–1989,rgery c November 2009
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DTABLE 1. Characteristics of 12,415 patients undergoing coronary artery bypass grafting during 1970–2003 in relation to time period of the
operation and diagnosis of type 2 diabetes mellitus
No diabetes, n ¼ 10,523 (85%) Type 2 diabetes, n ¼ 1892 (15%)
1970–1989,
n ¼ 3488 (33%),
mean ± SD
1990–1999,
n ¼ 5166 (49%),
mean ± SD
2000–2003,
n ¼ 1869 (18%),
mean ± SD P value*
1970–1989,
n ¼ 319 (17%),
mean ± SD
1990–1999,
n ¼ 989 (52%),
mean ± SD
2000–2003,
n ¼ 584 (31%),
mean ± SD P value*
Age (y) 58  8 65  10 66  10 <.01 59  8 65  9 67  9 <.01y
BMI (kg/m2) 26  3 26  4 26  4 .84 28  4 28  4 28  4 .81y
Creatinine
clearance (mL/
min)
82  23 79  27 82  27 .02 84  27 85  30 86  32 .59y
Female sex 14% 20% 21% <.01 20% 26% 25% .25y
Hypertension 24% 31% 63% <.01 52% 46% 75% <.01y
Diabetes
Insulin – – – – 25% 40% 52% <.01y
Oral drugs – – – – 51% 54% 65% <.01y
Diet treated – – – – 25% 14% 11% <.01y
Hyperlipidemia 7% 34% 73% <.01 13% 36% 75% <.01y
Previous AMI 52% 51% 51% .07 63% 54% 59% .26y
Acute coronary
syndrome
6% 27% 40% <.01 4% 29% 40% <.01y
History of stroke 3% 7% 7% <.01 4% 9% 12% <.01y
Peripheral vascular
disease
6% 6% 6% .39 11% 11% 10% .83y
Coronary disease
Single vessel 15% 7% 6% <.01 8% 3% 4% <.01y
Two vessel 33% 22% 20% 29% 17% 15%
Three vessel 50% 70% 73% 62% 80% 81%
Missing 2% 1% 0% 2% 0% 0%
Left main stem 13% 21% 26% <.01 14% 19% 22% <.01
LV function
Normal 59% 55% 64% .43 54% 49% 52% .39y
Reduced 35% 33% 26% 37% 37% 33%
Severely reduced 4% 7% 6% 7% 9% 11%
No information 2% 6% 5% 3% 5% 4%
No. of anastomoses
1–2 39% 16% 24% <.01 27% 11% 23% .01y
3–4 51% 70% 69% 58% 72% 70%
5–8 11% 15% 8% 15% 17% 8%
Use of ITA 73% 95% 95% <.01 81% 95% 95% <.01y
SD, Standard deviation; BMI, body mass index; AMI, acute myocardial infarction; LV, left ventricular; ITA, internal thoracic artery. *P value for trend. Age, body mass index, and
creatinine clearance are calculated with the crude model in regression analysis. Other P values are calculated by using the Mantel-Haenszel c2 test. yP<.001 for global difference
between patients with versus those without diabetes.despite the fact that they were, on average, 8 years younger
than patients operated on during 2000–2003. Unadjusted sur-
vival at 5 years was 89.5%, 89.9%, and 90.6% in patients
without DM operated on during 1970–1989, 1990–1999,
and 2000–2003, respectively. The corresponding figures
for patients with DM were 78.1%, 83.2%, and 81.7%.
Early mortality during 1970–2003 after a first isolated
CABG operation was 3.4% in patients with DM versus
1.8% in patients without DM, yielding a 2-fold higher risk
in patients with DM after multivariable correction for age
and other confounders (Table 2). There was no clear trend
over time periods in the ORs for early mortality in patients
with versus those without DM, but during the latest timeThe Journal of Thoracic and Caperiod (2000–2003), the OR was somewhat lower, with
a 95% CI including 1.0 (OR, 1.5; 95% CI, 0.8–2.9). Simi-
larly, late mortality among survivors at 30 days until 5 years
after the operation was almost 2 times higher after multi-
variable correction in patients with DM versus that seen in
patients without DM (HR, 1.8; 95% CI, 1.5–2.0). This
mortality disadvantage in patients with a diagnosis of DM
was essentially unchanged across the 3 time periods.
The multivariable adjusted risk of early death during
2000–2003 compared with 1970–1989 was significantly re-
duced both in patients with DM (OR, 0.3; 95% CI, 0.1–0.9)
and those without DM (OR, 0.4; 95% CI, 0.2–0.7), taking
changes in patient characteristics during the 3 decades intordiovascular Surgery c Volume 138, Number 5 1117
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DFIGURE 1. Annualized proportion of patients with type 2 diabetes mellitus among 12,415 patients undergoing isolated artery bypass grafting during 1970–
2003.account (Table 3). This is equivalent to a 2.1% average re-
duction of early mortality per year in patients with DM and
1.8% in patients without DM during the 33 years after cor-
rection for confounders. Furthermore, the multivariable cor-
rected risk of late death was similarly reduced by 40% in
patients with and in those without DM after CABG per-
formed during 2000–2003 compared with that seen in pa-
tients operated on during 1970–1989. The reduction in late
mortality per year was 2% (95% CI, 0%–4%) in patients
with DM and 3% (95% CI, 2%–4%) in those without DM.
Late mortality was significantly reduced in patients with
DM and insulin treatment or oral medication during 2000–
2003 compared with that seen during 1970–1989 (Table
4). Any change in mortality among the few patients who
had diet management only could not be assessed, as indi-
cated by the HRs with wide confidence limits.
FIGURE 2. Five-year survival after coronary artery bypass grafting
(CABG) performed during 1970–1989, 1990–1999, and 2000–2003, re-
spectively, in patients with and without type 2 diabetes mellitus (DM).
The y-axis ranges from 50% survival.1118 The Journal of Thoracic and Cardiovascular SuDISCUSSION
Consistent with other reports, we found that patients with
DM accepted for CABG were more likely to be female and
more often have comorbidities, such as higher BMI, previ-
ous stroke, history of hypertension, peripheral vascular dis-
ease, unstable coronary syndrome, poorer left ventricular
function, and more extensive coronary artery disease, than
patients without DM.5,7,10,13,14,20 Use of an arterial graft
and completeness of revascularization at the time of the op-
eration was equally high in our patients with and without
DM. Patients with type 2 DM included in our analyses fre-
quently had concurrent cardiovascular risk factors and
were usually initially not insulin dependent. Among the pa-
tients with DM, age and comorbidities increased during the 3
decades, whereas renal function and peripheral vascular dis-
ease did not change, indicating better preserved end-organ
function, probably as a result of recent improved medical
management and earlier diagnosis of DM because patients
operated on during 2000–2003 had shorter durations of
DM diagnosis than those undergoing CABG during
1990–1999. Type 2 DM with insulin resistance is closely
associated with the metabolic syndrome. Echahidi and co-
workers21 reported a 2.7–fold increase in the risk of death
within 30 days of CABG in patients with metabolic syn-
drome and DM and a 2.4-fold increased risk in patients
with metabolic syndrome without DM but no increased
risk in the patients with DM but not metabolic syndrome.
A variety of causes might explain a marked increase in
patients with DM having CABG, as also observed by other
authors.13 During the initial experience, surgeons were re-
luctant to accept patients for CABG with the peripherally lo-
cated coronary obstructions often observed in patients with
DM. Better recent recognition of a DM diagnosis might
also have contributed to the increase. Randomized trials
have shown that CABG is a better alternative thanrgery c November 2009
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DTABLE 2. Early and late mortality 30 days until 5 years after coronary artery bypass grafting during 3 time periods in patients with type 2 diabetes
mellitus compared with that seen in patients without diabetes mellitus
DM Deaths No DM Deaths Age adjusted Multivariable*
Time period No. n % No. n % OR 95% CI OR 95% CI
Early deaths
1970–2003 1892 64 3.4 10,523 187 1.8 1.8 1.4–2.4 2.0 1.4–2.7
1970–1989 319 11 3.5 3488 72 2.1 1.5 0.8–3.0 1.9 1.0–3.9
1990–1999 989 35 3.5 5166 79 1.5 2.5 1.6–3.8 2.8 1.7–4.4
2000–2003 584 18 3.1 1869 36 1.9 1.6 0.9–3.0 1.5 0.8–2.9
Late deaths HR 95% CI HR 95% CI
1970–2003 1828 267 14.6 10,336 859 8.3 1.7 1.5–2.0 1.8 1.5–2.0
1970–1989 308 59 19.2 3416 293 8.6 2.3 1.7–3.0 2.1 1.5–2.9
1990–1999 954 131 13.7 5087 444 8.7 1.7 1.4–2.0 1.7 1.4–2.1
2000–2003 566 77 13.6 1833 122 6.7 2.1 1.6–2.9 1.9 1.4–2.5
DM, Diabetes mellitus; OR, odds ratio; 95% CI, 95% confidence interval; HR, hazard ratio. *Adjusted for age, unstable angina pectoris, left ventricular function, creatinine clear-
ance, history of myocardial infarction, use of an internal thoracic artery graft, length, and weight.percutaneous coronary intervention (PCI) in patients with
DM and multivessel coronary artery disease because of
higher rates of complete revascularization and less risk of re-
peat revascularization.18,22 Cardiac death, myocardial in-
farction, or angina requiring revascularization occur less
frequently after CABG than after PCI in patients with DM
and multivessel coronary artery disease.12,23-25 The main
difference between the 2 treatments is that grafts are placed
distally on the coronary arteries, whereas PCI attacks the
proximal lesion. CABG bypasses a large amount of plaque
burden in the coronary arteries and inherently prevents rein-The Journal of Thoracic and Ctervention caused by progression of disease proximal to the
site of the coronary anastomoses, whereas PCI does not pre-
clude progression of lesions close to a stent. This might be of
major importance in patients with DM and an aggressive
generalized coronary atherosclerosis. Surgical revasculari-
zation is an effective treatment for patients with DM whose
coronary artery lesions do not qualify for endovascular re-
vascularization.26 The advantages seen with CABG over
those seen with balloon-only PCI in early trials might not
be applicable in the era of drug-eluting stents, glycoprotein
IIb/IIIa inhibitors, and the latest medical therapies.27 PCITABLE 3. Early and late mortality in survivors at 30 days until 5 years after coronary artery bypass grafting in patients with and without type 2
diabetes: Mortality during 1 time period compared with operations performed during 1970–1989
Time period
Deaths Age adjusted Multivariable*
No. n % OR 95%CI OR 95%CI
Early deaths
Diabetes
1970–1989 319 11 3.5 1 1
1990–1999 989 35 3.5 0.6 0.3–1.2 0.4 0.2–1.0
2000–2003 584 18 3.1 0.4 0.2–1.0 0.3 0.1–0.9
No diabetes
1970–1989 3488 72 2.1 1 1
1990–1999 5166 79 1.5 0.4 0.3–0.6 0.3 0.2–0.5
2000–2003 1869 36 1.9 0.5 0.3–0.8 0.4 0.2–0.7
HR 95% CI HR 95% CI
Late deaths
Diabetes
1970–1989 308 59 19.2 1 1
1990–1999 954 131 13.7 0.5 0.4–0.7 0.6 0.5–1.0
2000–2003 566 77 13.6 0.5 0.3–0.7 0.6 0.4–1.0
No diabetes
1970–1989 3416 293 8.6 1 1
1990–1999 5087 444 8.7 0.7 0.6–0.8 0.7 0.6–0.9
2000–2003 1833 122 6.6 0.5 0.4–0.6 0.6 0.5–0.8
OR, Odds ratio; 95% CI, 95% confidence interval; HR, hazard ratio. *Adjusted for age, unstable angina pectoris, left ventricular function, creatinine clearance, history of
myocardial infarction, use of an internal thoracic artery graft, length, and weight.ardiovascular Surgery c Volume 138, Number 5 1119
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DTABLE 4. Mortality at 5 years after CABG in patients with type 2 diabetes in relation to type of treatment: Time period of surgical intervention
compared with operations performed during 1970–1989
Deaths Crude Age adjusted Multivariable*
Time period No. n % HR 95% CI HR 95% CI HR 95% CI
Insulin 722 134 18.6
1970–1989 69 23 33.3 1 1 1
1990–1999 373 66 17.7 0.5 0.3–0.8 0.3 0.2–0.6 0.5 0.3–0.9
2000–2003* 280 45 16.1 0.4 0.3–0.7 0.3 0.2–0.5 0.4 0.2–0.7
Oral drugs 992 143 14.3
1970–1989 151 30 19.9 1 1 1
1990–1999 500 65 13.0 0.6 0.4–1.0 0.4 0.3–0.7 0.5 0.3–0.9
2000–2003* 341 47 13.8 0.7 0.4–1.1 0.4 0.3–0.7 0.6 0.3–1.0
Diet only 273 24 8.8
1970–1989 75 3 4.0 1 1 1
1990–1999 136 14 10.3 2.6 0.8–9.2 1.8 0.5–6.7 3.0 0.6–15.7
2000–2003 62 7 11.3 2.9 0.7–11.1 1.6 0.4–7.0 4.1 0.6–27.1
HR, Hazard ratio; 95%CI, 95% confidence interval. *Adjusted for age, unstable angina pectoris, left ventricular function, creatinine clearance, history of myocardial infarction, use
of an internal thoracic artery graft, length, and weight.might be a treatment of choice in patients with DM in case of
discrete lesions in large vessels and severe comorbidities and
if the internal thoracic artery cannot be used. Furthermore,
PCI might provide effective and safe treatment in case of re-
current symptoms after CABG and could thus have contrib-
uted to improved survival in patients undergoing operations
more recently. The number of patients with DM undergoing
revascularization is expected to increase because the preva-
lence of DM is increasing globally with a high incidence of
coronary artery disease.28
Our observational study includes all 12,415 first-time iso-
lated CABG procedures performed at one institution over
more than 3 decades. During this period, there was a consid-
erable increase in type 2 DM, patient age, and cardiovascular
risk factors and also changes in treatments. There were no
operations for unstable angina before 1980. Widespread sta-
tin treatment of patients with dyslipidemia was introduced
during the last decade. Overall early and 5-year multivari-
able adjusted mortality were about 2-fold higher in patients
with DM than in those without DM and possibly somewhat
lower in patients undergoing operations more recently. Dur-
ing 2000–2003, early and 5-year multivariable adjusted
mortality were substantially reduced compared with those
seen after operations performed during 1970–1989, irrespec-
tive of DM status. A significant reduction in early mortality
after adjustment for confounders was a result of improve-
ments of perioperative management in patients undergoing
cardiac surgery, such as technical development of pumps
and oxygenators, shorter operative times, less cooling, re-
fined careful surgical technique and handling of grafts,
methods of myocardial protection, anesthesiologic and
intensive care monitoring, and practices to deal with heart,
pulmonary, and renal failure in addition to the understanding
and introduction of effective antithrombotic regimens. Fur-
nary and associates9 documented that use of insulin infusion
reduced hospital mortality after CABG and also that1120 The Journal of Thoracic and Cardiovascular Sumortality in patients with DM, but not in those without
DM, decreased substantially during 1987–2001.
Early mortality is influenced by factors such as operative
technique and events occurring during the early recovery pe-
riod, whereas late mortality should be more influenced by
the patient’s cardiovascular risk factors, the extent of
coronary artery disease, and the degree of left ventricular
impairment and patency of inserted grafts. Survival after
CABG in patients with diabetes is greatly affected by asso-
ciated comorbidities of peripheral vascular disease and renal
failure.29 Diabetic patients treated with an early invasive
strategy for unstable angina and non–ST-segment elevation
myocardial infarction have a higher in-hospital and long-
term mortality that is largely explained by their less favor-
able baseline characteristics, including more advanced
coronary artery disease.20 Observed differences in survival
between CABG-treated patients with and without diabetes
might be largely a result of differential risk of mortality of
noncardiac causes.2 Patients with insulin-dependent type 2
DM who undergo CABG have a high rate of major compli-
cations and an extremely unfavorable short- and long-term
prognosis.8,13,17
The strength of the study was complete follow-up with
a unique personal number linked to national registers, allow-
ing every patient to be traced. Limitations were incomplete
data on the diagnosis of DM after hospital discharge. The in-
formation on DM reflected the situation at the time of the op-
eration. It goes without saying that during the years after the
operation, DM was diagnosed in many patients who were
originally not classified as having DM.30 Assumed inferior
results in these patients might tend to dilute the true differ-
ences in observed long-term mortality between patients
with and without DM. During the last decade, information
has evolved that many patients not having a diagnosis of
DM on admission have dysglycemia and a prediabetic state
with an impaired fasting glucose level, high level after oralrgery c November 2009
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that many patients listed as nondiabetic have disturbed glu-
cose homeostasis and an increased risk after CABG.31 Peri-
operative hyperglycemia is associated with longer
postoperative care and increased hospitalization costs.32
Only a few potential confounders were consistently avail-
able in the entire database and changed the multivariable ad-
justed point estimate by at least 10%. Patients in whom
medical treatment with b-blockers and statins was started af-
ter treatment for unstable coronary syndrome were classified
as having hypertension and hyperlipidemia, respectively, al-
though we did not have more detailed information about
blood pressures and lipid levels. We did not have valid infor-
mation on smoking habits. Diabetes is associated with dys-
lipidemia, in particular increased triglyceride levels and low
HDL cholesterol levels, as well as hypertension. Failure to
fully adjust for these factors in analyses of mortality most
likely resulted in residual confounding in estimates of ORs
and HRs, reflecting the increased risk associated with diabe-
tes. The net effect of residual confounding from major car-
diovascular risk factors might have been an overestimate
of the risk associated with diabetes.
An improved prognosis of survival after CABG over time
in patients with DM was anticipated because continuous dra-
matic advances in the medical treatment of patients with is-
chemic cardiovascular disease and DM have occurred. As
a consequence of guidelines, there is an increased awareness
to treat modifiable risk factors and comorbidities. Patients
are encouraged to reduce cardiovascular risk by means of
cessation of smoking, dietary modifications, and physical
exercise to treat obesity and control hyperlipidemia, hyper-
tension, and renal failure. Intensive glucose and tight blood
pressure control in patients will reduce the risk of diabetes-
related complications.33 ACE inhibitors reduce the risk of
cardiovascular complications in patients with DM, regard-
less of the antihypertensive effect.34 Likewise, statins reduce
the cardiovascular risk in patients with DM irrespective of
the cholesterol-lowering effect.35 Use of these 2 drugs in-
creased with time in our patients. In the United Kingdom
Prospective Diabetes Study, use of metformin reduced the
risk of myocardial infarction.36 We have documented an in-
creased use of medication in our patients, but unfortunately,
secondary prevention, such as uses of platelet inhibitors, sta-
tins, and ACE inhibitors and strict glycemic control, is
sometimes poorly applied.37
In conclusion, multivariable adjusted early mortality and
late mortality until 5 years after CABG were about 2-fold
greater in those with than in those without DM. The adjusted
risks of early and late death during 2000–2003 compared
with that during 1970–1989 were exceptionally reduced
both in those with and without DM. Despite medical
advances, late mortality after CABG in patients with DM
undergoing operations recently remained increased.The Journal of Thoracic and CaWe are grateful to Christian Unge, Henrik Overo¨dder, Bjo¨rn
To¨rnkvist, Anders Giesecke, Anna Olofsson, Susanne Hylander,
and Emelie Ivert for collecting information from the medical
records.
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